Treatment and prognosis of kidney disease in multiple myeloma and other monoclonal gammopathies
- S Vincent Rajkumar, MD
S Vincent Rajkumar, MD
- Edward W. and Betty Knight Scripps Professor of Medicine
- Mayo Clinic
- Andre A Kaplan, MD
Andre A Kaplan, MD
- Professor of Medicine
- University of Connecticut Health Center
- Nelson Leung, MD
Nelson Leung, MD
- Professor of Medicine
- Mayo Clinic College of Medicine
- Section Editors
- Richard J Glassock, MD, MACP
Richard J Glassock, MD, MACP
- Editor-in-Chief — Nephrology
- Section Editor — Glomerular Diseases
- Emeritus Professor
- The David Geffen School of Medicine at UCLA
- Robert A Kyle, MD
Robert A Kyle, MD
- Section Editor — Plasma Cell Disorders
- Professor of Medicine
- Mayo Medical School
Kidney disease is a common complication in patients with multiple myeloma and other monoclonal gammopathies . A wide range of renal manifestations and pathologies involving different mechanisms have been described with these disorders. Kidney injury most often occurs in patients with a high tumor burden and can evolve as either an acute or chronic disorder .
This topic will review the treatment of kidney disease in patients with multiple myeloma or other monoclonal gammopathies, with a focus on light chain cast nephropathy. The epidemiology, pathogenesis, etiology, clinical features, evaluation, and diagnosis of kidney disease in multiple myeloma and other monoclonal gammopathies are presented separately. (See "Epidemiology, pathogenesis, and etiology of kidney disease in multiple myeloma and other monoclonal gammopathies" and "Clinical features, evaluation, and diagnosis of kidney disease in multiple myeloma and other monoclonal gammopathies".)
The pathogenesis and treatment of amyloidosis and light and heavy chain deposition diseases, and treatment of multiple myeloma, are discussed elsewhere. (See "Pathogenesis of immunoglobulin light chain (AL) amyloidosis and light and heavy chain deposition diseases" and "Overview of the management of multiple myeloma".)
PATIENTS WITH ACUTE OR SUBACUTE KIDNEY INJURY
Acute (AKI) or subacute kidney injury in patients with multiple myeloma and other monoclonal gammopathies results from a variety of mechanisms. These include light chain cast nephropathy, hypercalcemia, nephrotoxic agents (eg, radiocontrast, nonsteroidal anti-inflammatory drugs [NSAIDs]), and, infrequently, hyperviscosity syndrome and severe hyperuricemia. Specific treatment is directed at the cause of AKI [3-8]. Dialysis should be performed for the usual indications. (See "Renal replacement therapy (dialysis) in acute kidney injury in adults: Indications, timing, and dialysis dose" and "Indications for initiation of dialysis in chronic kidney disease".)
Light chain cast nephropathy (myeloma kidney) — Light chain cast nephropathy occurs most often in patients with high rates of production and excretion of immunoglobulin free light chains, which may be toxic to the tubules and form obstructing tubular casts, particularly if the patient is volume depleted . Light chain cast nephropathy should be treated urgently to restore renal function.
Subscribers log in hereLiterature review current through: Jul 2017. | This topic last updated: Jan 13, 2017.References
- Bladé J, Fernández-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158:1889.
- Winearls CG. Acute myeloma kidney. Kidney Int 1995; 48:1347.
- Rota S, Mougenot B, Baudouin B, et al. Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore) 1987; 66:126.
- Cohen DJ, Sherman WH, Osserman EF, Appel GB. Acute renal failure in patients with multiple myeloma. Am J Med 1984; 76:247.
- Uchida M, Kamata K, Okubo M. Renal dysfunction in multiple myeloma. Intern Med 1995; 34:364.
- Zucchelli P, Pasquali S, Cagnoli L, Ferrari G. Controlled plasma exchange trial in acute renal failure due to multiple myeloma. Kidney Int 1988; 33:1175.
- Misiani R, Tiraboschi G, Mingardi G, Mecca G. Management of myeloma kidney: an anti-light-chain approach. Am J Kidney Dis 1987; 10:28.
- Johnson WJ, Kyle RA, Pineda AA, et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy. Arch Intern Med 1990; 150:863.
- Sanders PW, Booker BB. Pathobiology of cast nephropathy from human Bence Jones proteins. J Clin Invest 1992; 89:630.
- Ludwig H, Adam Z, Hajek R, et al. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol 2010; 28:4635.
- Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol 2012; 30:2946.
- Ballester OF, Tummala R, Janssen WE, et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997; 20:653.
- Hutchison CA, Bradwell AR, Cook M, et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4:745.
- Hutchison CA, Cockwell P, Stringer S, et al. Early reduction of serum-free light chains associates with renal recovery in myeloma kidney. J Am Soc Nephrol 2011; 22:1129.
- Alexanian R, Barlogie B, Dixon D. Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990; 150:1693.
- Kaplan AA. Therapeutic apheresis for the renal complications of multiple myeloma and the dysglobulinemias. Ther Apher 2001; 5:171.
- Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 2003; 4:379.
- Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005; 143:777.
- Cserti C, Haspel R, Stowell C, Dzik W. Light-chain removal by plasmapheresis in myeloma-associated renal failure. Transfusion 2007; 47:511.
- Leung N. Plasma exchange in multiple myeloma. Ann Intern Med 2006; 144:455; author reply 455.
- Leung N, Gertz MA, Zeldenrust SR, et al. Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008; 73:1282.
- Clark WF, Garg AX. Plasma exchange for myeloma kidney: cast(s) away? Kidney Int 2008; 73:1211.
- Burnette BL, Leung N, Rajkumar SV. Renal improvement in myeloma with bortezomib plus plasma exchange. N Engl J Med 2011; 364:2365.
- Chow CC, Mo KL, Chan CK, et al. Renal impairment in patients with multiple myeloma. Hong Kong Med J 2003; 9:78.
- Knudsen LM, Hjorth M, Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65:175.
- Pozzi C, Pasquali S, Donini U, et al. Prognostic factors and effectiveness of treatment in acute renal failure due to multiple myeloma: a review of 50 cases. Report of the Italien Renal Immunopathology Group. Clin Nephrol 1987; 28:1.
- Ying WZ, Allen CE, Curtis LM, et al. Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model. J Clin Invest 2012; 122:1777.
- Munier A, Gras V, Andrejak M, et al. Zoledronic Acid and renal toxicity: data from French adverse effect reporting database. Ann Pharmacother 2005; 39:1194.
- Yui JC, Van Keer J, Weiss BM, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol 2016; 91:E348.
- Hobeika L, Self SE, Velez JC. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. BMC Nephrol 2014; 15:156.
- Lodhi A, Kumar A, Saqlain MU, Suneja M. Thrombotic microangiopathy associated with proteasome inhibitors. Clin Kidney J 2015; 8:632.
- Iggo N, Palmer AB, Severn A, et al. Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med 1989; 73:903.
- Korzets A, Tam F, Russell G, et al. The role of continuous ambulatory peritoneal dialysis in end-stage renal failure due to multiple myeloma. Am J Kidney Dis 1990; 16:216.
- Torra R, Bladé J, Cases A, et al. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91:854.
- Sharland A, Snowdon L, Joshua DE, et al. Hemodialysis: an appropriate therapy in myeloma-induced renal failure. Am J Kidney Dis 1997; 30:786.
- Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114:822.
- Dagher F, Sammett D, Abbi R, et al. Renal transplantation in multiple myeloma. Case report and review of the literature. Transplantation 1996; 62:1577.
- Leung N, Lager DJ, Gertz MA, et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004; 43:147.
- Heher EC, Spitzer TR, Goes NB. Light chains: heavy burden in kidney transplantation. Transplantation 2009; 87:947.
- Heher EC, Spitzer TR. Hematopoietic stem cell transplantation in patients with chronic kidney disease. Semin Nephrol 2010; 30:602.
- Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011; 91:672.
- Stokes MB, Valeri AM, Herlitz L, et al. Light Chain Proximal Tubulopathy: Clinical and Pathologic Characteristics in the Modern Treatment Era. J Am Soc Nephrol 2016; 27:1555.
- PATIENTS WITH ACUTE OR SUBACUTE KIDNEY INJURY
- Light chain cast nephropathy (myeloma kidney)
- - Overview of approach
- - Treatment
- Anti-myeloma therapy
- Fluid management
- Extracorporeal methods for light chain removal
- - Protocol for plasmapheresis
- - Efficacy studies
- - Prevention
- - Prognosis
- - Future directions
- Nephrotoxic agents
- Less common causes of AKI
- - Plasma cell infiltration
- - Hyperuricemia
- - Interstitial nephritis
- - Hyperviscosity
- - Thrombotic microangiopathy
- PATIENTS WITH CHRONIC KIDNEY DISEASE
- End-stage renal disease
- Kidney transplantation
- PATIENTS WITH ALBUMINURIA OR NEPHROTIC SYNDROME
- Monoclonal immunoglobulin deposition disease
- Monoclonal cryoglobulinemia
- Membranoproliferative glomerulonephritis
- Fibrillary glomerulonephritis and immunotactoid glomerulopathy
- PATIENTS WITH ELECTROLYTE ABNORMALITIES
- Light chain proximal tubulopathy (Fanconi syndrome)
- SOCIETY GUIDELINE LINKS
- INFORMATION FOR PATIENTS
- SUMMARY AND RECOMMENDATIONS
- Acute (AKI) or subacute kidney injury
- Albuminuria or nephrotic syndrome
- Electrolyte abnormalities